Can Total Thrombus-formation Analysis System (T-TAS®) better predict coagulation disturbances than conventional laboratory measurements in patients with polycystic ovary syndrome?

Abstract

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

The Use of Total Thrombus Formation Analysis System as a Tool to Assess Platelet Function in Bleeding and Thrombosis Risk—A Systematic Review

“…Furthermore, T-TAS has been demonstrated to be a useful tool in the study of thrombus formation in blood taken from animal models such as monkeys [31] and mice [18,33,43]. T-TAS may be useful for patients with diseases such as COVID-19 [7] or PCOS [11]. On the other hand, dabigatran was a therapy in patients in the analysis by Taune et al [17] In order to determine the optimal concentration for the evaluation of pathologic arterial thrombus formation, there are ongoing evaluations of blood samples from those patients with cerebrovascular disease and coronary atherosclerosis.…”

“…Ożegowska et al [11] analysed T-TAS in terms of determining the risk of coagulation disorders in women with polycystic ovary syndrome (PCOS). This study compared T-TAS (AR-chip) with classic coagulation parameters such as RBC, white blood cells (WBC), haematocrit, platelets, antithrombin, D-dimer, fibrinogen, prothrombin time (PT), international normalized ratio (INR) and prothrombin index (PI).…”

“…The T-TAS parameters were also independent of body mass index (BMI). Researchers found that increased triglyceride levels in PCOS patients increased AUC30 and decreased the time of thrombus formation initiation (T10) and OT, but more research is needed to determine the usefulness of T-TAS in this group of patients [11]. On the other hand, Osiński et al [12] assessed whether in pregnant women with type 1 diabetes glycaemic control influences the prothrombotic and antifibrinolytic status.…”